Alira Health’s Transformation Talks: Real-World Data to Support HTAs in Europe

Published on:
April 28, 2022

In this new episode titled “Real-World Data to Support HTAs in Europe”, we will examine the various uses of Real-World Data (RWD) and how it is valued in Health Technology Assessments in multiple European nations. Learn more about using RWD as support in HTAs and its direct impact on HTAs budgets, results, and even patient outcomes by listening to this episode of Transformation Talks.

Meet our guests:

Catia Proenca – Director, Clinical Real-World Evidence, Alira Health 

Catia designs and manages Real-World Evidence strategies maintaining a Market Access perspective by ensuring key stakeholder needs (e.g., HTA, payers) are met, thus, maximizing access to innovation, and ultimately improving patient outcomes. With 13+ years of experience in industry and academia, Catia’s previous roles include positions at Wellmera, Novartis Global, and the Novartis Institute for Biomedical Research. Catia holds a Ph.D. in Neuroscience from the Weill Cornell Medical College, New York, and the University of Lisbon. 

Carsten Schwenke – HTA Expert

Carsten Schwenke is a licensed biostatistician and health economist, with a Ph.D. in public health, that has 25 years of experience in the pharmaceutical sector, focusing on clinical development and market access. He has been self-employed for the past 15 years, with a primary focus on the German HTA process. 

Meet our host:

Kenny Carberry – Director, Clinical Development, Alira Health 

Kenny leads business development efforts and initiatives for early-stage healthcare companies. His background covers various indications across pharma, medical devices, and digital health. In addition to his expertise in business development, Kenny has several years of experience in clinical trial operations and management. He offers a unique perspective on the clinical development lifecycle, from generating a comprehensive strategy to executing a successful trial. 


Related news

Blog May 4, 2023
How to Leverage Real-World Evidence to Achieve Orphan Drug Designation
Obtaining an orphan drug designation (ODD) is challenging and may require sponsors to leverage real-world evidence (RWE). Read the article to learn what ODD is, why it matters, and how RWE can help.
Orphan Drug Rare Disease Real-World Evidence (RWE)
Events April 26, 2023
MedTech Forum 2023
We are excited to share that we will be sponsoring and speaking at MedTech Forum 2023. The MedTech Forum is the largest health and medical technology industry conference in Europe and(...)
MedTech Real-World Evidence (RWE)
Blog April 17, 2023
Reimbursement of Rare Disease Drugs in Italy: Challenges and Hopes for the Future
When it comes to rare diseases, Italy has done a good job in bringing EMA-approved drugs, including orphan drugs, to the Italian market. But  multiple challenges exist, many of which(...)
Italy Market Access Pharma Rare Disease Real-World Evidence (RWE)
Blog April 17, 2023
Pharmaceutical Market Access in the UK: A Changing Landscape
Start reading this interview with Rachel Fyson to gain insight into the changing landscape of market access in the United Kingdom.
Market Access Pharma UK
Blog April 14, 2023
Lifecycle Optimization: The Path to Commercial Success
Pharmaceutical and biotech companies constantly focus on product innovation. But how can you also increase your effectiveness in order to be as commercially competitive and efficient as possible?
Market Access MedTech Pharma
News April 5, 2023
Alira Health Joins EMIG to Advance Market Access in the UK
We are pleased to announce that Alira Health has joined the Ethical Medicines Industry Group (EMIG), a multi-stakeholder network and trade association that represents the interests(...)
Market Access Patient Centricity UK
Events April 3, 2023
Reuters Pharma 2023
We are pleased to share that we will be participating in Reuters Pharma 2023 as speakers and sponsors. Join us on the 1st day of the event for the panel “Unleash RWE’s benefits(...)
Pharma Real-World Evidence (RWE)
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.